Compile Data Set for Download or QSAR
maximum 50k data
Found 159 with Last Name = 'buggy' and Initial = 'jj'
TargetHistone deacetylase 1(Homo sapiens (Human))
Celera Genomics

LigandPNGBDBM24621(CG-003 | N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-...)
Affinity DataKi:  4nM ΔG°:  -47.5kJ/molepH: 7.4 T: 2°CAssay Description:HDAC activity was measured using a continuous trypsin-coupled assay. For inhibitor characterization, measurements were done using 96-well assay plat...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHistone deacetylase 1(Homo sapiens (Human))
Celera Genomics

LigandPNGBDBM24620(CG-002 | N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}n...)
Affinity DataKi:  6nM ΔG°:  -46.5kJ/molepH: 7.4 T: 2°CAssay Description:HDAC activity was measured using a continuous trypsin-coupled assay. For inhibitor characterization, measurements were done using 96-well assay plat...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHistone deacetylase 1(Homo sapiens (Human))
Celera Genomics

LigandPNGBDBM24622(3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoy...)
Affinity DataKi:  7nM ΔG°:  -46.1kJ/molepH: 7.4 T: 2°CAssay Description:HDAC activity was measured using a continuous trypsin-coupled assay. For inhibitor characterization, measurements were done using 96-well assay plat...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHistone deacetylase 3(Homo sapiens (Human))
Celera Genomics

LigandPNGBDBM24622(3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoy...)
Affinity DataKi:  8.20nM ΔG°:  -45.7kJ/molepH: 7.4 T: 2°CAssay Description:HDAC activity was measured using a continuous trypsin-coupled assay. For inhibitor characterization, measurements were done using 96-well assay plat...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHistone deacetylase 6(Homo sapiens (Human))
Celera Genomics

LigandPNGBDBM24622(3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoy...)
Affinity DataKi:  17nM ΔG°:  -43.9kJ/molepH: 7.4 T: 2°CAssay Description:HDAC activity was measured using a continuous trypsin-coupled assay. For inhibitor characterization, measurements were done using 96-well assay plat...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHistone deacetylase 2(Homo sapiens (Human))
Celera Genomics

LigandPNGBDBM24622(3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoy...)
Affinity DataKi:  19nM ΔG°:  -43.6kJ/molepH: 7.4 T: 2°CAssay Description:HDAC activity was measured using a continuous trypsin-coupled assay. For inhibitor characterization, measurements were done using 96-well assay plat...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPolyamine deacetylase HDAC10(Homo sapiens (Human))
Celera Genomics

LigandPNGBDBM24622(3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoy...)
Affinity DataKi:  24nM ΔG°:  -43.1kJ/molepH: 7.4 T: 2°CAssay Description:HDAC activity was measured using a continuous trypsin-coupled assay. For inhibitor characterization, measurements were done using 96-well assay plat...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHistone deacetylase 1(Homo sapiens (Human))
Celera Genomics

LigandPNGBDBM24618(CG-001 | N-hydroxy-4-[2-(phenylformamido)ethoxy]be...)
Affinity DataKi:  43nM ΔG°:  -41.6kJ/molepH: 7.4 T: 2°CAssay Description:HDAC activity was measured using a continuous trypsin-coupled assay. For inhibitor characterization, measurements were done using 96-well assay plat...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHistone deacetylase 8(Homo sapiens (Human))
Celera Genomics

LigandPNGBDBM24622(3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoy...)
Affinity DataKi:  280nM ΔG°:  -37.0kJ/molepH: 7.4 T: 2°CAssay Description:HDAC activity was measured using a continuous trypsin-coupled assay. For inhibitor characterization, measurements were done using 96-well assay plat...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHistone deacetylase 1(Homo sapiens (Human))
Celera Genomics

LigandPNGBDBM24623(4-[2-({3-[(dimethylamino)methyl]-1-benzofuran-2-yl...)
Affinity DataKi: >5.00E+4nM ΔG°: >-24.3kJ/molepH: 7.4 T: 2°CAssay Description:HDAC activity was measured using a continuous trypsin-coupled assay. For inhibitor characterization, measurements were done using 96-well assay plat...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetReceptor tyrosine-protein kinase erbB-4(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.100nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Blk(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  0.200nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191606(US9181263, 23 | US9278100, 23)
Affinity DataIC50:  0.320nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191605(US9181263, 14 | US9278100, 14)
Affinity DataIC50:  0.390nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Fgr(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  0.400nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Blk(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191617(US9181263, 13 | US9278100, 13)
Affinity DataIC50:  0.670nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191622(US9181263, 18)
Affinity DataIC50:  0.760nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Yes(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  0.800nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytoplasmic tyrosine-protein kinase BMX(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.800nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191614(US9181263, 10 | US9278100, 10)
Affinity DataIC50:  0.880nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191628(US9181263, 24 | US9278100, 24)
Affinity DataIC50:  0.890nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191608(US9181263, 11)
Affinity DataIC50:  0.920nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  1nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  1nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  1nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase HCK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  1nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  1nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytoplasmic tyrosine-protein kinase BMX(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  1.10nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97675(US8476284, 43 | US8497277, 15 | US9133201, 15 | US...)
Affinity DataIC50:  1.10nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Lyn(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  1.20nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191614(US9181263, 10 | US9278100, 10)
Affinity DataIC50:  1.31nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191616(US9181263, 12 | US9278100, 12)
Affinity DataIC50:  1.33nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191622(US9181263, 18)
Affinity DataIC50:  1.38nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191613(US9181263, 8 | US9278100, 8)
Affinity DataIC50:  1.40nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191617(US9181263, 13 | US9278100, 13)
Affinity DataIC50:  1.56nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191626(US9181263, 22 | US9278100, 22)
Affinity DataIC50:  1.57nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191623(US9181263, 19 | US9278100, 19)
Affinity DataIC50:  1.58nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  2nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  2nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191621(US9181263, 17 | US9278100, 17)
Affinity DataIC50:  2nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191621(US9181263, 17 | US9278100, 17)
Affinity DataIC50:  2.07nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191609(US9181263, 3 | US9278100, 3)
Affinity DataIC50:  2.10nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase CSK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  2.20nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191605(US9181263, 14 | US9278100, 14)
Affinity DataIC50:  2.30nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Fgr(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  2.30nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 159 total ) | Next | Last >>
Jump to: